Expectations Synergy Pharmceuticals (SGYP) would report $0.20 per share in losses were high, but the company missed by $0.03/sh. So what? Hints the company would sell the company mattered more. Given the stock is up 20% in the last month, investors are not at all worried.In the press release, Synergy mentioned launching its drug without any partners. Plecanatide and Dolc are big products. $SGYPQ, SYNERGY PHARMACEUTICALS INC DEL / 60 Looking ahead, if SGYP is looking to sell its product on its own, it will need to sell shares, diluting shareholders slightly.Short-term pain for all the gain.Further reading:3 Biotech stocks with upsideForget Valeant, look at ProgenicsValeant Pharmaceuticals: Is this a Short Attack?Heron Flying to the Moon. What's Next...